Corient Private Wealth LLC Sells 14,464 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Corient Private Wealth LLC reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 71.5% during the fourth quarter, Holdings Channel reports. The firm owned 5,779 shares of the biopharmaceutical company’s stock after selling 14,464 shares during the period. Corient Private Wealth LLC’s holdings in Halozyme Therapeutics were worth $276,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth $29,000. Smartleaf Asset Management LLC boosted its position in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at $69,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 322 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research analyst reports. Benchmark reissued a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Trading Down 0.0 %

Halozyme Therapeutics stock opened at $63.81 on Tuesday. The stock has a market cap of $7.88 billion, a P/E ratio of 18.60, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $66.00. The firm’s fifty day moving average price is $59.34 and its 200-day moving average price is $54.84. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 31,697 shares of company stock worth $1,754,451. 2.40% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.